Tg(PDGFB-LRRK2*G2019S)340Djmo

The G2019S-LRRK2 transgene was designed with a minimal cytomegalovirus (CMV) enhancer and human platelet derived growth factor, B polypeptide (PDGFB) promoter/enhancer elements driving expression of a full length human leucine-rich repeat kinase 2 (LRRK2) cDNA. LRRK2 cDNA was modified by targeted mutation of the LRRK2 locus to harbor the LRRK2*G2019S mutation associated with autosomal dominant, late-onset Parkinson's disease. Line 340 was generated. (J:171645)